Prevention of a virus propagation based on cellular factors controlling HIV infection
| Project/Area Number |
15H04659
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Environmental and hygienic pharmacy
|
|---|
| Research Institution | Kumamoto University |
|---|
Principal Investigator |
Shogo Misumi 熊本大学, 大学院生命科学研究部(薬), 教授 (40264311)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
高宗 暢暁 熊本大学, 熊本創生推進機構, 准教授 (60322749)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2017: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2015: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
|---|
| Keywords | HIV-1 / 宿主因子 / ウィルス / 衛生 / 感染症 / 新規治療戦略開発 / HIV感染症 / 治療戦略 |
|---|
| Outline of Final Research Achievements |
In this study, we showed that glycolysis enzymes GAPDH, Enolase, PKM 2 inhibit HIV-1 replication. In particular, GAPDH and PKM 2 inhibited HIV-1 replication by inhibiting packaging of tRNALys3, a reverse transcriptase primer, into viral particles. Moreover, we demonstrated that the uncoating process of HIV-1 is suppressed by FDA-approved Trametinib. These findings are useful for the development of a more effective anti-HIV strategy.
|
Report
(4 results)
Research Products
(30 results)
